THE SCIENCE

Clinical Studies

“The scientific community is now recognizing over three decades of our research and development showing that ParActin with its andrographolides have great potential to be the next new class of anti-inflammatory agents”.  Annie Eng, Founder and CEO. As verified in a recent article in the scientific journal Biochemical Pharmacology. 

 

We have come to understand how ParActin effectively turns off the “master power switch” NFκB, responsible for exerting the over-reactive inflammatory response. By deactivating NF-kB, the hyperexpression of cytokines, pro-inflammatory proteins and enzymes such as COX-2, PGE2, interleukin-2, interferon gamma is reduced.  The result: Healthy Bone, Joint, Muscle, Cartilage, Brain and Immune Support are favorably promoted.

 

Because ParActin crosses the blood brain barrier, we believe ParActin works more efficiently, effectively than most other anti-inflammatory that may have bioavailability challenges.

 

We will continue to invest in further clinical trials to continue to validate ParActin’s unique and potent viability.

  • 1. “Efficacy of an Andrographis paniculata Composition for the Relief of Rheumatoid Arthritis Symptoms: A Prospective Randomized Placebo-Controlled Trial.”

    R.A. Burgos et al.,  Published Clinical Rheumatology 28 (8), 931-946 (2009)

    In a randomized, double blind, and placebo-controlled study published in Clinical Rheumatology 2009, 60 individuals with compromised joints were given 100 mg of ParActin® or placebo three times a day for 14 weeks in conjunction with Methothrexate (MTX), the standard therapy for RA. MTX induces significant improvement in the number of tender and swollen joints, pain, and functional status.  However, long term use of MTX may cause serious infection and liver damage.

     

    ParActin® was effective in reducing number and total grade of swollen joints, number and total grade of tender joints, HAQ-52, and SF-36 (two health questionnaires).  The effect was associated with reduction of Rheumatoid Factor (RF), creatine kinase, IgA-RF and IgM-RF.  IgA and IgM are antibodies made by your body’s immune system in response to foreign substance attack such as  bacteria, viruses, fungus, and so on.  Patients with RA typically have elevated levels of RF, IgA-RF, IgM-RF and C-Reactive Protein.  The reduction in IgA –RF and IgM-RF are beneficial as there is positive correlation with  cartilage damage.

     

    The ParActin® group showed significant improvement compared to placebo with MTX group in the following scores:

    • number of swollen joints (ParActin® 9 vs Placebo 13)
    • total grade of swollen joint (ParActin® 11 vs Placebo 16)
    • total grade of tender joints (ParActin® 14 vs Placebo 17)
    • HAQ (ParActin® 19 vs Placebo 24)
    • reduction of rheumatoid factor (ParActin® 119 vs Placebo 130)
    • reduction in IgA (ParActin® 293.7 vs placebo 335)

     

    The study concludes that ParActin® was significantly effective in reducing symptoms and serological parameters and therefore useful as complementary natural treatment for rheumatoid arthritis.

  • 2. “Andrographolide a New Potential Drug for the Long Term Treatment of Rheumatoid Arthritis Disease.”

    M. Hidalgo et al. Published Innovative Rheumatology, 256-259 (2013)

     

    In another human clinical trial published in Innovative Rheumatology 2013, 8 individuals with various rheumatoid conditions were given 300 mg of ParActin® daily for 4 years.  Treatment with ParActin® showed significant improvement in number of swollen joints, total grade of swollen joint, total grade of tender joints, and improvement in quality of life.

     

    Also noted were significant reductions in Rheumatoid Factor (RF), erythrocytes sedimentation rate, and C-Reactive Protein.  Further, serum immunological parameters of inflammation were reduced progressively during 48 month of ParActin® supplementation.

     

    ParActin® may have additional therapeutic effects over Prednisone and MTX in reducing pain and fatigue. Andrographolide inhibits COX-2 enzyme and reduces prostaglandin production that is tied to pain and inflammation.

     

    After 24 months of taking ParActin®, 6 individuals progressed to supplementing with ParActin® as monotherapy.  No side effects were observed, indicating ParActin® was safe, non-toxic, and well tolerated.